agxАндрология и генитальная хирургияAndrology and Genital Surgery2070-97812412-890210.62968/2070-9781-2024-25-1-24-30agx-732Research ArticleОБЗОРНАЯ СТАТЬЯREVIEWСпособы клинического применения маркеров литогенной активности при мочекаменной болезниClinical Applications of the Markers of Lithogenic Activity in Kidney Stone Diseasehttps://orcid.org/0000-0002-9064-7881АлфимовА. Е.AlfimovA. E.

к.м.н., ведущий научный сотрудник Института цифровой медицины 

ID РИНЦ 4354-7081 

Москва, 119991, ул. Трубецкая, д. 8, стр. 2   +7 985 9544730 

Cand.Med.Sci., Research Fellow 

alfimov_a_e@staff.sechenov.ruhttps://orcid.org/0000-0001-5238-0680АлексееваД. Ю.AlexeevaD. Yu.

студент 4-го курса Международной школы «Медицина будущего» 

Москва, 119991, ул. Трубецкая, д. 8, стр. 2    +7 964 590-28-29 

alekseeva_d_yu1@student.sechenov.ruКоролевД. О.KorolevD. O.ГориноваД. М.GorinovaD. M.ЕникеевМ. Э.EnikeevM. E.РапопортЛ. М.RapoportL. M.ФГАОУ ВО «Первый МГМУ имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияDigital Medicine Institution of FGAOU VO I.M. Sechenov First Moscow State Medical UniversityRussian FederationФГАОУ ВО «Первый МГМУ имени И.М. Сеченова» Минздрава России (Сеченовский университет)Russian FederationФГАОУ ВО «Первый МГМУ имени И.М. Сеченова» Минздрава России (Сеченовский университет), Институт урологии и репродуктивного здоровья человека Первого МГМУ им. И.М. СеченоваRussian Federation2024080520242512430Copyright © Алфимов А.Е., Алексеева Д.Ю., Королев Д.О., Горинова Д.М., Еникеев М.Э., Рапопорт Л.М., 20242024Алфимов А.Е., Алексеева Д.Ю., Королев Д.О., Горинова Д.М., Еникеев М.Э., Рапопорт Л.М.Alfimov A.E., Alexeeva D.Y., Korolev D.O., Gorinova D.M., Enikeev M.E., Rapoport L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://agx.elpub.ru/jour/article/view/732

Маркеры литогенной активности (ЛА) – это лабораторные или инструментальные тесты, указывающие на степень выраженности патологического процесса, приводящего к образованию новых или росту имеющихся камней в верхних мочевых путях.

В предшествующем обзоре мы выделили 6 групп маркеров ЛА.

В настоящем обзоре мы описываем способы клинического применения маркеров ЛА, которые авторы и разработчики данных тестов упоминают в своих публикациях.

Важными способами клинического применения маркеров ЛА являются выявление периодов высокой литогенной активности и контроль эффективности метафилактики МКБ.

Так как эти способы требуют регулярного, а иногда и частого выполнения тестов, необходима адаптация маркеров ЛА для применения в домашних условиях с подключением к системе дистанционного мониторинга.

.

мочекаменная болезньидиопатический кальциевый нефролитиазметафилактикаактивность литогенного процессамаркер литогенной активностиReferencesRule AD, Lieske JC, Li X, et al. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014;25(12):2878-2886. PMID: 25104803. doi: 10.1681/ ASN.2013091011.Rule AD, Lieske JC, Li X, et al. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014;25(12):2878-2886. PMID: 25104803. doi: 10.1681/ ASN.2013091011.Laube N, Pullmann M. The use of risk indices: do they predict recurrence? Yes, they (at least some) do. Urol Res. 2006 Apr;34(2):118-21. PMID: 16397777. doi: 10.1007/s00240-005-0022-4.Laube N, Pullmann M. The use of risk indices: do they predict recurrence? Yes, they (at least some) do. Urol Res. 2006 Apr;34(2):118-21. PMID: 16397777. doi: 10.1007/s00240-005-0022-4.D’Costa MR, Pais VM, Rule AD. Leave no stone unturned: defining recurrence in kidney stone formers. Curr Opin Nephrol Hypertens. 2019 Mar;28(2):148-153. PMID: 30531469. doi: 10.1097/MNH.0000000000000478.D’Costa MR, Pais VM, Rule AD. Leave no stone unturned: defining recurrence in kidney stone formers. Curr Opin Nephrol Hypertens. 2019 Mar;28(2):148-153. PMID: 30531469. doi: 10.1097/MNH.0000000000000478.Daudon M, Hennequin C, Boujelben G, et al. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int. 2005 May;67(5):1934-43. PMID: 15840041. doi: 10.1111/j.1523-1755.2005.00292.x.Daudon M, Hennequin C, Boujelben G, et al. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int. 2005 May;67(5):1934-43. PMID: 15840041. doi: 10.1111/j.1523-1755.2005.00292.x.Gambaro G, Croppi E, Coe F, et al. Consensus Conference Group. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016 Dec;29(6):715-734. PMID: 27456839. doi: 10.1007/s40620-016-0329-y.Gambaro G, Croppi E, Coe F, et al. Consensus Conference Group. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016 Dec;29(6):715-734. PMID: 27456839. doi: 10.1007/s40620-016-0329-y.Williams JC Jr, Gambaro G, Rodgers A, et al. Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis. 2021 Feb;49(1):1-16. PMID: 33048172. doi: 10.1007/s00240-020-01217-3.Williams JC Jr, Gambaro G, Rodgers A, et al. Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis. 2021 Feb;49(1):1-16. PMID: 33048172. doi: 10.1007/s00240-020-01217-3.Williams JC, Al-Awadi H, Muthenini M, et al. Stone morphology distinguishes two pathways of idiopathic calcium oxalate stone pathogenesis. J Endourol. 2021 Dec 17. PMID: 34915736. doi: 10.1089/end.2021.0685.Williams JC, Al-Awadi H, Muthenini M, et al. Stone morphology distinguishes two pathways of idiopathic calcium oxalate stone pathogenesis. J Endourol. 2021 Dec 17. PMID: 34915736. doi: 10.1089/end.2021.0685.Estrade V, Denis de Senneville B, Meria P, et al. Toward improved endoscopic examination of urinary stones: a concordance study between endoscopic digital pictures vs microscopy. BJU Int. 2021 Sep;128(3):319-330. PMID: 33263948. doi: 10.1111/bju.15312.Estrade V, Denis de Senneville B, Meria P, et al. Toward improved endoscopic examination of urinary stones: a concordance study between endoscopic digital pictures vs microscopy. BJU Int. 2021 Sep;128(3):319-330. PMID: 33263948. doi: 10.1111/bju.15312.D’Costa MR, Haley WE, Mara KC, et al. Symptomatic and Radiographic Manifestations of Kidney Stone Recurrence and Their Prediction by Risk Factors: A Prospective Cohort Study. J Am Soc Nephrol. 2019 Jul;30(7):1251-1260. PMID: 31175141. doi: 10.1681/ASN.2018121241.D’Costa MR, Haley WE, Mara KC, et al. Symptomatic and Radiographic Manifestations of Kidney Stone Recurrence and Their Prediction by Risk Factors: A Prospective Cohort Study. J Am Soc Nephrol. 2019 Jul;30(7):1251-1260. PMID: 31175141. doi: 10.1681/ASN.2018121241.Sutherland. J. W., Parks, J. H. and Coe, F. L.: Recurrence after a single renal stone in a community practice. Miner. Electrolyte Metab., 11: 267, 1985. PMID: 4033604.Sutherland. J. W., Parks, J. H. and Coe, F. L.: Recurrence after a single renal stone in a community practice. Miner. Electrolyte Metab., 11: 267, 1985. PMID: 4033604.Johnson, C. M., Wilson, D. M., OFallon, W. M., et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int., 16 624, 1979. PMID: 548606.doi: 10.1038/ki.1979.173.Johnson, C. M., Wilson, D. M., OFallon, W. M., et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int., 16 624, 1979. PMID: 548606.doi: 10.1038/ki.1979.173.Ahlstrand, C. and Tiselius, H. G.: Recurrences during a 10-year follow-up after first renal stone episode. Urol. Res., 18: 397, 1990. PMID: 2100415. doi: 10.1007/BF00297372.Ahlstrand, C. and Tiselius, H. G.: Recurrences during a 10-year follow-up after first renal stone episode. Urol. Res., 18: 397, 1990. PMID: 2100415. doi: 10.1007/BF00297372.Ljunghall. S., Danielson, B. G.: A prospective study of renal stone recurrences. Brit. J. Urol., 56: 122, 1984. PMID: 6498430 doi: 10.1111/j.1464-410x.1984.tb05346.xLjunghall. S., Danielson, B. G.: A prospective study of renal stone recurrences. Brit. J. Urol., 56: 122, 1984. PMID: 6498430 doi: 10.1111/j.1464-410x.1984.tb05346.xМетодология дистанционного мониторинга пациентов с мочекаменной болезнью: разработка и первичная апробация / Г. С. Лебедев, И. А. Шадеркин, М. А. Газимиев и др // Урология. 2021;5:26– 34), PMID: 34743428.Lebedev G, Shaderkin I, Gazimiev M. et al. Remote monitoring of kidney stone patients: methodology development and initial evaluation. Urologiia. 2015;5:82–84. Russian. PMID: 34743428.Daudon M, Hennequin C, Boujelben G, et al. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int. 2005 May;67(5):1934-43. PMID: 15840041. doi: 10.1111/j.1523-1755.2005.00292.x.Daudon M, Hennequin C, Boujelben G, et al. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int. 2005 May;67(5):1934-43. PMID: 15840041. doi: 10.1111/j.1523-1755.2005.00292.x.Lindberg JS, Cole FE, Romani W, et al. Calcium Oxalate Stone Agglomeration Inhibition [tm] Reflects Renal Stone-Forming Activity. Ochsner J. 2000 Apr;2(2):68-78. PMID: 21811395.Lindberg JS, Cole FE, Romani W, et al. Calcium Oxalate Stone Agglomeration Inhibition [tm] Reflects Renal Stone-Forming Activity. Ochsner J. 2000 Apr;2(2):68-78. PMID: 21811395.Шустер П. И., Глыбочко П.В. Состояние процессов камнеобразования в почках на фоне андрогенной терапии, Саратовский научно-медицинский журнал, vol. 5, no. 4, 2009.Шустер П. И., Глыбочко П.В. Состояние процессов камнеобразования в почках на фоне андрогенной терапии, Саратовский научно-медицинский журнал, vol. 5, no. 4, 2009.Grases F, García-Ferragut L, Costa-Bauzá A, et al. Simple test to evaluate the risk of urinary calcium stone formation. Clin Chim Acta. 1997 Jul 4;263(1):43-55. PMID: 9247727 . doi: 10.1016/s0009-8981(97)06554-6.Grases F, García-Ferragut L, Costa-Bauzá A, et al. Simple test to evaluate the risk of urinary calcium stone formation. Clin Chim Acta. 1997 Jul 4;263(1):43-55. PMID: 9247727 . doi: 10.1016/s0009-8981(97)06554-6.Tiselius HG. Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate? Urolithiasis. 2015 Jan;43 Suppl 1:47-57. PMID: 25086904. doi: 10.1007/s00240-014-0698-4.Tiselius HG. Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate? Urolithiasis. 2015 Jan;43 Suppl 1:47-57. PMID: 25086904. doi: 10.1007/s00240-014-0698-4.Marickar YM, Salim A. Temporary risk identification in urolithiasis. Urol Res. 2009 Dec;37(6):377-80. PMID: 19830414. doi: 10.1007/s00240-009-0225-1.Marickar YM, Salim A. Temporary risk identification in urolithiasis. Urol Res. 2009 Dec;37(6):377-80. PMID: 19830414. doi: 10.1007/s00240-009-0225-1.Rodriguez A, Cunha TDS, Rodgers AL, et al. Comparison of Supersaturation Outputs from Different Programs and Their Application in Testing Correspondence with Kidney Stone Composition. J Endourol. 2021 May;35(5):687-694. PMID: 33050741. doi: 10.1089/end.2020.0894.Rodriguez A, Cunha TDS, Rodgers AL, et al. Comparison of Supersaturation Outputs from Different Programs and Their Application in Testing Correspondence with Kidney Stone Composition. J Endourol. 2021 May;35(5):687-694. PMID: 33050741. doi: 10.1089/end.2020.0894.Marangella M, Petrarulo M, Vitale C, et al. LITHORISK.COM: the novel version of a software for calculating and visualizing the risk of renal stone. Urolithiasis. 2021 Jun;49(3):211-217. PMID: 33245396. doi: 10.1007/s00240-020-01228-0.Marangella M, Petrarulo M, Vitale C, et al. LITHORISK.COM: the novel version of a software for calculating and visualizing the risk of renal stone. Urolithiasis. 2021 Jun;49(3):211-217. PMID: 33245396. doi: 10.1007/s00240-020-01228-0.Tiselius H-G (1997) Risk formulas in calcium oxalate urolithiasis. World J Urol 15:176. PMID: 9228725. doi: 10.1007/BF02201855Tiselius H-G (1997) Risk formulas in calcium oxalate urolithiasis. World J Urol 15:176. PMID: 9228725. doi: 10.1007/BF02201855Robertson WG. A risk factor model of stone-formation. Front Biosci. 2003 Sep 1;8:s1330-8. PMID: 12957848. doi: 10.2741/1181.Robertson WG. A risk factor model of stone-formation. Front Biosci. 2003 Sep 1;8:s1330-8. PMID: 12957848. doi: 10.2741/1181.Robertson WG. Methods for diagnosing the risk factors of stone formation. Arab J Urol. 2012 Sep;10(3):250-7. PMID: 26558033. doi: 10.1016/j.aju.2012.03.006.Robertson WG. Methods for diagnosing the risk factors of stone formation. Arab J Urol. 2012 Sep;10(3):250-7. PMID: 26558033. doi: 10.1016/j.aju.2012.03.006.Ganter, K., Bongartz, D. & Hesse, A. Tamm-Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. Urology 53, 492–495 (1999). PMID: 10096372 DOI: 10.1016/s0090-4295(98)00581-0.Ganter, K., Bongartz, D. & Hesse, A. Tamm-Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. Urology 53, 492–495 (1999). PMID: 10096372 DOI: 10.1016/s0090-4295(98)00581-0.Wu J, Zhao J, Zhao Z, et al. Significance of TRPV5 and OPN biomarker levels in clinical diagnosis of patients with early urinary calculi. Am J Transl Res. 2021 Jun 15;13(6):6778-6783. PMID: 34306426.Wu J, Zhao J, Zhao Z, et al. Significance of TRPV5 and OPN biomarker levels in clinical diagnosis of patients with early urinary calculi. Am J Transl Res. 2021 Jun 15;13(6):6778-6783. PMID: 34306426.Boonla C, Wunsuwan R, Tungsanga K, et al. Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res. 2007 Aug;35(4):185-91. PMID: 17541572. doi: 10.1007/s00240-007-0098-0.Boonla C, Wunsuwan R, Tungsanga K, et al. Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res. 2007 Aug;35(4):185-91. PMID: 17541572. doi: 10.1007/s00240-007-0098-0.Tsujihata M, Tsujikawa K, Tei N, et al. Urinary macromolecules and renal tubular cell protection from oxalate injury: comparison of normal subjects and recurrent stone formers. Int J Urol. 2006 Mar;13(3):197-201. PMID: 16643608. doi: 10.1111/j.1442-2042.2006.01271.xTsujihata M, Tsujikawa K, Tei N, et al. Urinary macromolecules and renal tubular cell protection from oxalate injury: comparison of normal subjects and recurrent stone formers. Int J Urol. 2006 Mar;13(3):197-201. PMID: 16643608. doi: 10.1111/j.1442-2042.2006.01271.xGolovanov S.A., Sinyukhin V.N., Tashlitsky V.A., et al. Urinary excretion of tryptophan, lysine, trimethyllysine, sarcosine, choline and 4-pyridoxic acid in urolithiasis. Experimental and Clinical Urology 2022;15(1):68-75;Golovanov S.A., Sinyukhin V.N., Tashlitsky V.A., et al. Urinary excretion of tryptophan, lysine, trimethyllysine, sarcosine, choline and 4-pyridoxic acid in urolithiasis. Experimental and Clinical Urology 2022;15(1):68-75;Голованов С.А., Синюхин В.Н., Ташлицкий В.А., и др.. Экскреция триптофана, лизина, триметиллизина, саркозина, холина и 4-пиридоксиновой кислоты с мочой при мочекаменной болезни. Экспериментальная и клиническая урология 2022;15(1):68-75; https://doi.org/10.29188/2222-8543-2022-15-1-68-75Голованов С.А., Синюхин В.Н., Ташлицкий В.А., и др.. Экскреция триптофана, лизина, триметиллизина, саркозина, холина и 4-пиридоксиновой кислоты с мочой при мочекаменной болезни. Экспериментальная и клиническая урология 2022;15(1):68-75; https://doi.org/10.29188/2222-8543-2022-15-1-68-75Silverio AA, Chung WY, Cheng C, et al. The potential of at-home prediction of the formation of urolithiasis by simple multifrequency electrical conductivity of the urine and the comparison of its performance with urine ion-related indices, color and specific gravity. Urolithiasis. 2016 Apr;44(2):127-34. PMID: 22301017. doi: 10.1007/s00240-015-0812-2.Silverio AA, Chung WY, Cheng C, et al. The potential of at-home prediction of the formation of urolithiasis by simple multifrequency electrical conductivity of the urine and the comparison of its performance with urine ion-related indices, color and specific gravity. Urolithiasis. 2016 Apr;44(2):127-34. PMID: 22301017. doi: 10.1007/s00240-015-0812-2.Kavouras SA, Suh HG, Vallet M, et al. Urine osmolality predicts calcium-oxalate crystallization risk in patients with recurrent urolithiasis. Urolithiasis. 2021 Oct;49(5):399-405. PMID: 33635363. doi: 10.1007/s00240-020-01242-2..Kavouras SA, Suh HG, Vallet M, et al. Urine osmolality predicts calcium-oxalate crystallization risk in patients with recurrent urolithiasis. Urolithiasis. 2021 Oct;49(5):399-405. PMID: 33635363. doi: 10.1007/s00240-020-01242-2..Shoag J, Eisner BH. Relationship between C-reactive protein and kidney stone prevalence. J Urol 2014;191:372-5. PMID: 24071479. doi: 10.1016/j.juro.2013.09.033Shoag J, Eisner BH. Relationship between C-reactive protein and kidney stone prevalence. J Urol 2014;191:372-5. PMID: 24071479. doi: 10.1016/j.juro.2013.09.033Mao W, Wu J, Zhang Z, et al. Neutrophil-lymphocyte ratio acts as a novel diagnostic biomarker for kidney stone prevalence and number of stones passed. Transl Androl Urol. 2021 Jan;10(1):77- 86. PMID: 33532298. doi: 10.21037/tau-20-890.Mao W, Wu J, Zhang Z, et al. Neutrophil-lymphocyte ratio acts as a novel diagnostic biomarker for kidney stone prevalence and number of stones passed. Transl Androl Urol. 2021 Jan;10(1):77- 86. PMID: 33532298. doi: 10.21037/tau-20-890.Kang HW, Seo SP, Kim WT, et al. Hypertriglyceridemia is associated with increased risk for stone recurrence in patients with urolithiasis. Urology. 2014 Oct;84(4):766-71. PMID: 25106943. doi: 10.1016/j.urology.2014.06.013.Kang HW, Seo SP, Kim WT, et al. Hypertriglyceridemia is associated with increased risk for stone recurrence in patients with urolithiasis. Urology. 2014 Oct;84(4):766-71. PMID: 25106943. doi: 10.1016/j.urology.2014.06.013.Sonmez MG, Kozanhan B, Deniz ÇD, et al. Dynamic thiol/ disulfide homeostasis as a novel indicator of oxidative stress in patients with urolithiasis. Investig Clin Urol. 2019 Jul;60(4):258- 266. PMID: 31294135. doi: 10.4111/icu.2019.60.4.258.Sonmez MG, Kozanhan B, Deniz ÇD, et al. Dynamic thiol/ disulfide homeostasis as a novel indicator of oxidative stress in patients with urolithiasis. Investig Clin Urol. 2019 Jul;60(4):258- 266. PMID: 31294135. doi: 10.4111/icu.2019.60.4.258.Ciudin A, Luque MP, Salvador R, et al. Abdominal computed tomography--a new tool for predicting recurrent stone disease. J Endourol. 2013 Aug;27(8):965-9. PMID: 23668633. doi: 10.1089/end.2013.0161.Ciudin A, Luque MP, Salvador R, et al. Abdominal computed tomography--a new tool for predicting recurrent stone disease. J Endourol. 2013 Aug;27(8):965-9. PMID: 23668633. doi: 10.1089/end.2013.0161.Ciudin A, Luque MP, Salvador R, et al. The evolution of CT diagnosed papillae tip microcalcifications: can we predict the development of stones? J Endourol. 2014 Aug;28(8):1016-21. PMID: 24735416. doi: 10.1089/end.2014.0151.Ciudin A, Luque MP, Salvador R, et al. The evolution of CT diagnosed papillae tip microcalcifications: can we predict the development of stones? J Endourol. 2014 Aug;28(8):1016-21. PMID: 24735416. doi: 10.1089/end.2014.0151.Ferraro PM, Vittori M, Macis G, et al. Changes in renal papillary density after hydration therapy in calcium stone formers. BMC Urol. 2018 Nov 12;18(1):101. PMID: 30419887. doi: 10.1186/s12894-018-0415-7.Ferraro PM, Vittori M, Macis G, et al. Changes in renal papillary density after hydration therapy in calcium stone formers. BMC Urol. 2018 Nov 12;18(1):101. PMID: 30419887. doi: 10.1186/s12894-018-0415-7.Borofsky MS, Paonessa JE, Evan AP, et al. A Proposed Grading System to Standardize the Description of Renal Papillary Appearance at the Time of Endoscopy in Patients with Nephrolithiasis. J Endourol. 2016 Jan;30(1):122-7. PMID: 26414908. doi: 10.1089/end.2015.0298.Borofsky MS, Paonessa JE, Evan AP, et al. A Proposed Grading System to Standardize the Description of Renal Papillary Appearance at the Time of Endoscopy in Patients with Nephrolithiasis. J Endourol. 2016 Jan;30(1):122-7. PMID: 26414908. doi: 10.1089/end.2015.0298.Almeras C, Pradere B, Estrade V, et al. On Behalf Of The Lithiasis Committee Of The French Urological Association. Endoscopic Papillary Abnormalities and Stone Recognition (EPSR) during Flexible Ureteroscopy: A Comprehensive Review. J Clin Med. 2021 Jun 29;10(13):2888. PMID: 34209668. doi: 10.3390/jcm10132888.Almeras C, Pradere B, Estrade V, et al. On Behalf Of The Lithiasis Committee Of The French Urological Association. Endoscopic Papillary Abnormalities and Stone Recognition (EPSR) during Flexible Ureteroscopy: A Comprehensive Review. J Clin Med. 2021 Jun 29;10(13):2888. PMID: 34209668. doi: 10.3390/jcm10132888.Robertson WG, Peacock M, Marshall RW, et al. Saturationinhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med. 1976;294(5):249- 252. PMID: 1244550. doi:10.1056/NEJM197601292940504.Robertson WG, Peacock M, Marshall RW, et al. Saturationinhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med. 1976;294(5):249- 252. PMID: 1244550. doi:10.1056/NEJM197601292940504.Hallson PC, Rose GA. A new urinary test for stone «activity». Br J Urol. 1978 Dec;50(7):442-8. PMID: 753493. doi: 10.1111/j.1464-410x.1978.tb06188.x.Hallson PC, Rose GA. A new urinary test for stone «activity». Br J Urol. 1978 Dec;50(7):442-8. PMID: 753493. doi: 10.1111/j.1464-410x.1978.tb06188.x.Pak CY, Galosy RA. Propensity for spontaneous nucleation of calcium oxalate. Quantitative assessment by urinary FPR-APR discriminant score. Am J Med. 1980;69(5):681-689. PMID: 7435510. doi:10.1016/0002-9343(80)90418-0.Pak CY, Galosy RA. Propensity for spontaneous nucleation of calcium oxalate. Quantitative assessment by urinary FPR-APR discriminant score. Am J Med. 1980;69(5):681-689. PMID: 7435510. doi:10.1016/0002-9343(80)90418-0.Nicar MJ, Hill K, Pak CY. A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. Metabolism. 1983 Sep;32(9):906-10. PMID: 6888271.doi: 10.1016/0026-0495(83)90205-6.Nicar MJ, Hill K, Pak CY. A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. Metabolism. 1983 Sep;32(9):906-10. PMID: 6888271.doi: 10.1016/0026-0495(83)90205-6.Tiselius HG. Measurement of the risk of calcium phosphate crystallization in urine. Urol Res. 1987;15(2):79-81. doi: 10.1007/BF00260937. PMID: 3590433.Tiselius HG. Measurement of the risk of calcium phosphate crystallization in urine. Urol Res. 1987;15(2):79-81. doi: 10.1007/BF00260937. PMID: 3590433.Erwin DT, Kok DJ, Alam J, et al. Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton. Am J Kidney Dis. 1994 Dec;24(6):893-900. PMID: 7985666. doi: 10.1016/s0272-6386(12)81057-2.Erwin DT, Kok DJ, Alam J, et al. Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton. Am J Kidney Dis. 1994 Dec;24(6):893-900. PMID: 7985666. doi: 10.1016/s0272-6386(12)81057-2.Lindberg JS, Cole FE, Romani W, et al. Calcium Oxalate Stone Agglomeration Inhibition [tm] Reflects Renal Stone-Forming Activity. Ochsner J. 2000 Apr;2(2):68-78. PMID: 21811395.Lindberg JS, Cole FE, Romani W, et al. Calcium Oxalate Stone Agglomeration Inhibition [tm] Reflects Renal Stone-Forming Activity. Ochsner J. 2000 Apr;2(2):68-78. PMID: 21811395.Grases F, García-Ferragut L, Costa-Bauzá A, et al. Simple test to evaluate the risk of urinary calcium stone formation. Clin Chim Acta. 1997 Jul 4;263(1):43-55. PMID: 9247727.ndoi: 10.1016/s0009-8981(97)06554-6.Grases F, García-Ferragut L, Costa-Bauzá A, et al. Simple test to evaluate the risk of urinary calcium stone formation. Clin Chim Acta. 1997 Jul 4;263(1):43-55. PMID: 9247727.ndoi: 10.1016/s0009-8981(97)06554-6.Шатохина С.Н., Шабалин В.Н. Ранняя диагностика уролитиаза, определение степени его активности и состава камнеобразующих солей мочи (система Литос. Урология и нефрология. 1998. № 1. С. 19–23)).Shatokhina, S. N., & Shabalin, V. N. Early diagnosis of urolithiasis, assessment of its activity and composition of lithogenic urine salts (Litos system). Urologiia i nefrologiia, 1998 (1), 19–23.Laube N, Berg W, Bernsmann F, et al. Induced urinary crystal formation as an analytical strategy for the prediction and monitoring of urolithiasis and other metabolism-related disorders. EPMA J. 2014 Aug 16;5(1):13. doi: 10.1186/1878-5085-5-13. PMID: 25206937.Laube N, Berg W, Bernsmann F, et al. Induced urinary crystal formation as an analytical strategy for the prediction and monitoring of urolithiasis and other metabolism-related disorders. EPMA J. 2014 Aug 16;5(1):13. doi: 10.1186/1878-5085-5-13. PMID: 25206937.Yang, B. et al. Calcium oxalate crystallization index (COCI): an alternative method for distinguishing nephrolithiasis patients from healthy individuals. Ann. Clin. Lab. Sci. 44, 262–271 (2014). PMID: 25117095.Yang, B. et al. Calcium oxalate crystallization index (COCI): an alternative method for distinguishing nephrolithiasis patients from healthy individuals. Ann. Clin. Lab. Sci. 44, 262–271 (2014). PMID: 25117095.More-Krong P, Tubsaeng P, Madared N, et al. Clinical validation of urinary indole-reacted calcium oxalate crystallization index (iCOCI) test for diagnosing calcium oxalate urolithiasis. Sci Rep. 2020 May 20;10(1):8334. PMID: 32433482.doi: 10.1038/s41598-020-65244-1.More-Krong P, Tubsaeng P, Madared N, et al. Clinical validation of urinary indole-reacted calcium oxalate crystallization index (iCOCI) test for diagnosing calcium oxalate urolithiasis. Sci Rep. 2020 May 20;10(1):8334. PMID: 32433482.doi: 10.1038/s41598-020-65244-1.Porowski T, Kirejczyk JK, Mrozek P, et al.. Upper metastable limit osmolality of urine as a predictor of kidney stone formation in children. Urolithiasis. 2019 Apr;47(2):155-163. PMID: 29356875. doi: 10.1007/s00240-018-1041-2.Porowski T, Kirejczyk JK, Mrozek P, et al.. Upper metastable limit osmolality of urine as a predictor of kidney stone formation in children. Urolithiasis. 2019 Apr;47(2):155-163. PMID: 29356875. doi: 10.1007/s00240-018-1041-2.

The authors declare that there are no conflicts of interest present.